Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
 BACK TO LIST

European Patient Summary

Patient
Name: Mäkelä, Katja
DOB: 28-NOV-1954 (Age: 71)
Gender: female
ID: 6615-747498-3 (ECI)
Author
dr Kivistö, Juhani
Patient summary Document
European Patient Summary
Report Date: 21-MAR-2025

Problem list

Condition Onset Date / Period Status
Acute ST segment elevation myocardial infarction 29-Apr-2023 active
Metabolic syndrome X 10-Dec-2008 active
Essential hypertension 05-Dec-2007 active
Hyperlipidemia 29-Nov-2006 active
Anemia 01-Mar-1995 active
Emphysematous bronchitis 24-Jun-1981 active
Myocardial infarction 29-Apr-2023 - 29-Apr-2023 inactive
Concussion with no loss of consciousness 03-Oct-2021 - 06-Dec-2021 inactive
Concussion injury of brain 03-Oct-2021 - 06-Dec-2021 inactive
Streptococcal sore throat 04-Aug-2020 - 12-Aug-2020 inactive
Viral sinusitis 21-Mar-2016 - 10-Apr-2016 inactive
Acute viral pharyngitis 19-Sep-2015 - 27-Sep-2015 inactive

Medication list

Medication Since Form Dosage Reason
Simvastatin 10 mg oral tablet 2025-03-21 - 1 tablet (10 mg) by mouth once daily Hyperlipidemia
60 ACTUAT Fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler 2025-03-12 - 1 inhalation (250 micrograms / 50 micrograms) twice daily Chronic obstructive bronchitis (disorder)
Albuterol (as albuterol sulfate) 5 mg/mL solution for inhalation 2025-03-12 - 2.5 mg (0.5 mL of 5 mg/mL solution) via nebulizer every 4 to 6 hours as needed Chronic obstructive bronchitis (disorder)
Amlodipine (as amlodipine besylate) 2.5 mg oral tablet 2025-03-12 - 1 tablet (2.5 mg) by mouth once daily Essential hypertension (disorder)
Hydrochlorothiazide 25 mg oral tablet 2025-03-12 - 1 tablet (25 mg) by mouth once daily Essential hypertension (disorder)
Aspirin 81 mg gastro-resistant oral tablet 2023-04-29 - 1 tablet (81 mg) by mouth once daily -
Atorvastatin (as atorvastatin calcium) 40 mg oral tablet 2023-04-29 - 1 tablet (40 mg) by mouth once daily -
Labetalol hydrochloride 200 mg oral tablet 2023-04-29 - 1 tablet (200 mg) twice daily -
Losartan potassium 100 mg oral tablet 2023-04-29 - 1 tablet (100 mg) by mouth once daily -

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 12-Mar-2025
Clostridium tetani toxoid antigen adsorbed only vaccine product 23-Feb-2022
SARS-CoV-2 mRNA vaccine 07-Apr-2021
Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F capsular polysaccharide antigens conjugated only vaccine product 25-Jan-2017
Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, capsular polysaccharide conjugated antigens only vaccine product 20-Jan-2016

Procedure History list

Procedure Date Reason
Laboratory test 29-Apr-2023 -
Electrocardiographic procedure 29-Apr-2023 -
Angiography of coronary artery 29-Apr-2023 -
Diagnostic assessment 29-Apr-2023 -
Plain X-ray of chest 29-Apr-2023 -
Percutaneous coronary intervention 29-Apr-2023 Acute ST segment elevation myocardial infarction (disorder)
Transthoracic echocardiography 29-Apr-2023 -
Consultation for treatment 29-Apr-2023 -
Assessment of cardiac status using monitoring device 29-Apr-2023 -
Patient discharge 20-Mar-2016 -
Hospice care 19-Mar-2016 -
Notifications 03-Feb-2016 -
Certification procedure 03-Feb-2016 -
Initial patient assessment 03-Feb-2016 -
Development of individualized plan of care 03-Feb-2016 -

Allergies and Intolerances

No known allergies or intolerances

Care Plan

Active Planned Care / Goals Start Date Reason
Discharge care plan 29-Apr-2023 -
Lifestyle education regarding hypertension 05-Dec-2007 Essential hypertension (disorder)
  • Achieve and maintain systolic blood pressure below 130 mmHg through lifestyle modifications.
  • Achieve and maintain diastolic blood pressure below 80 mmHg through lifestyle modifications.
Hyperlipidemia clinical management plan 20-Dec-2006 Hyperlipidemia (disorder)
  • Achieve LDL cholesterol below 70 mg/dL
  • Achieve total cholesterol below 200 mg/dL
  • Achieve HDL cholesterol above 50 mg/dL
  • Achieve triglycerides below 150 mg/dL
Diabetes self management plan 21-Sep-1994 Prediabetes (finding)
  • Maintain fasting plasma glucose within the recommended range for prediabetes
  • Maintain HbA1c below the threshold for diabetes diagnosis
Chronic obstructive pulmonary disease clinical management plan 24-Jun-1981 Chronic obstructive bronchitis (disorder)
  • Patient will stop smoking to reduce COPD progression and exacerbations
  • Maintain oxygen saturation above 88% at rest
  • Reduce COPD exacerbations to less than 2 per year
  • Patient will walk at least 100 meters in 6 minutes
  • Patient will receive annual influenza and recommended pneumococcal vaccinations
Immunization Recommendation Due Date Reason
Influenza virus antigen only vaccine product 01-Oct-2026 Annual seasonal influenza vaccination

Vital Signs

Vital Signs 2025-03-12 2024-03-06
Body Height 173.9 cm 173.9 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 0 {score} 1 {score}
Body Weight 83.3 kg 83.3 kg
Body mass index (BMI) [Ratio] 27.6 kg/m2 27.6 kg/m2
Heart rate 82 /min 71 /min
Respiratory rate 13 /min 14 /min
Blood pressure panel with all children optional 106 mm[Hg] 98 mm[Hg]

Relevant diagnostic tests/laboratory data

Recent Lab Observations 21-MAR-2025 Reference Range Unit
Glucose [Mass/volume] in Blood 83.2 70 - 100 mg/dL
Urea nitrogen [Mass/volume] in Blood 9.9 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 3.3 H 0.6 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 8.8 8.6 - 10.3 mg/dL
Sodium [Moles/volume] in Blood 142.6 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.9 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 107.7 98 - 110 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 24.5 22 - 29 mmol/L
Protein [Mass/volume] in Serum or Plasma 6.9 6.6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 3.9 3.5 - 5.0 g/dL
Globulin [Mass/volume] in Serum by calculation 3.2 L 25 - 35 g/L
Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 0.1 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 129.7 H 32 - 91 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 49.1 7 - 56 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 25.0 10 - 40 U/L
Cholesterol [Mass/volume] in Serum or Plasma 166.4 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 199.7 H 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 100.2 H 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 32.9 L 40 - 60 mg/dL

Device Use

Device Date (since)
Blood glucose meter (physical object) 21-Sep-1994